{"title":"Application of health education based on the integrated theory of health behavior change in the pelvic floor rehabilitation of patients with cervical cancer after radical surgery","authors":"","doi":"10.22514/ejgo.2023.062","DOIUrl":"https://doi.org/10.22514/ejgo.2023.062","url":null,"abstract":"To analyze the effect of applying health education based on the integrated theory of health behavior change in the pelvic floor rehabilitation of patients with cervical cancer after radical surgery. We recruited 130 patients with cervical cancer who underwent gynecological surgery in our hospital between the 01 February 2021 and the 01 March 2022. According to the random number table method, the patients were divided into a control group and an observation group (65 cases per group). The control group received routine health education, while the observation group received health education based on the integrated theory of health behavior change. We compared the two groups with regards to pelvic floor function, quality-of-life, and psychological status before and after intervention by analyzing PFDI-20 (Pelvic Floor Distress Inventory Questionnaire-20), PFIQ-7 (Pelvic Floor Impact Questionnaire-7), HAMA (Hamilton Anxiety Scale) and HAMD (Hamilton Depression Scale) questionnaires, treatment compliance and nursing satisfaction. After intervention, the PFDI-20 scores and total scores of patients in the observation group were lower than those in the control group (p < 0.05). The PFIQ-7 scores and total scores of patients in the observation group were lower than those in the control group (p < 0.05). The HAMA and HAMD scores in the observation group were significantly lower than those in the control group (p < 0.05). The treatment compliance and nursing satisfaction rate of patients in the observation group were higher than those in the control group (p < 0.05). Health education based on the integrated theory of health behavior change can improve pelvic floor muscle strength, the quality-of-life, and the treatment compliance of patients after radical surgery for cervical cancer. In addition, this strategy can alleviate anxiety and depression, and improve nursing satisfaction and is worthy of wider clinical application.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"88 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Molybdenum target X-ray examination and multimodality MRI in the diagnosis of breast cancer","authors":"","doi":"10.22514/ejgo.2023.064","DOIUrl":"https://doi.org/10.22514/ejgo.2023.064","url":null,"abstract":"Breast cancer is one of the most common malignant diseases, with a high mortality rate, affecting mostly females. This study aims to assess the diagnostic value of Molybdenum target X-ray examination and multimodality Magnetic Resonance Imaging (MRI) in breast cancer diagnosis. A total of 60 patients with suspected breast cancer were screened and included in the study. All patients underwent Molybdenum target X-ray and multimodality MRI, and the results were compared to pathological examination, which served as the reference standard for evaluating the diagnostic efficacy of the different screening methods. Molybdenum target X-ray examination identified 19 positive cases and 41 negative cases. Comparatively, multimodality MRI detected 43 positive cases and 17 negative cases. Compared to Molybdenum target X-ray, multimodality MRI demonstrated higher diagnostic accuracy, specificity, and sensitivity. Further analysis revealed that among the 45 positive patients, 13 were classified as stage 1, 20 as stage 2, 9 as stage 3, and 3 as stage 4. The pathological types were categorized as invasive ductal carcinoma, intraductal carcinoma, and ductal carcinoma in situ, with 25, 6 and 14 cases, respectively. Intraductal carcinoma exhibited higher levels of enhancement rate and signal enhancement ratio, as well as shorter peak time, compared to the other two types. No significant difference was observed between invasive ductal carcinoma and ductal carcinoma in situ. In the clinical diagnosis of breast cancer, multimodality MRI examination proves to be more comprehensive and accurate in determining the tumor’s nature and the type of disease, with significant clinical value in the field.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"2014 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Xiaojing Sun, Xinyue Zhang, Lanhui Yuan, Yu-Qin Fu, N Concin, X Matias-Guiu, I Vergote, D Cibula, M Mirza, S Marnitz, V Makker, M Taylor, C Aghajanian, A Oaknin, J Mier, A Cohn, J Perera, P Hoskin, X Liang, H Zeng, S Chen, M Jiang, S Liu, Fan, Y Zhang, W Zhao, Z Chen, X Zhao, P Ren, M Zhu, J Guo, X Cui, X Zhang, H Qian, H Duan, Y Zhang, F D'amico, E Skarmoutsou, M Libra, G Luo, M Tang, Q Zhao, L Lu, Y Xie, Y Li, Z Lu, S Zheng, C Liu, X Wang, G Zhang, F Wang, K Dey, R Bharti, G Dey, I Pal, Y Rajesh, S Chavan, E Asl, M Amini, S Najafi, B Mansoori, A Mokhtarzadeh, A Mohammadi, H Park, K Baek, J Wang, P Xu, X Yang, Q Yu, X Xu, G Zou, L Gonzalez, K Garrie, M Turner, P Singh, S Ali, S Doi, N Fujioka, S Ohtsuka, R Kondo, M Yamamoto, M Denda, C Allgwer, A Kretz, Von Karstedt, S Wittau, M Henne-Bruns, D Lemke, J, D Dowarha, R Chou, C Yu, D Meng, R Sun, G Liu, L Peng, L Zheng, P Xie, G Huang, J Zhang, G Qing, D Liu, X Wang, Y Chen, H Xu, H Song, Q Zhou, P Huang, J Xue, Y Cong, Y Cui, S Wang, L Jiang, J Cao, S Zhu, Q Sun, Y Cao, Y Lan, L Lei, B Zhang, S Wang, G Peng, S Tsukamoto, K Okumura, H Ogawa, S Ikeda, F Niyonsaba, M Muoio, M Talia, R Lappano, A Sims, V Vella, F Cirillo, S Mishra, M Charan, R Shukla, P Agarwal, S Misri, A Verma, J Anjum, S Mitra, R Das, R Alam, A Mojumder, T Emran, G Bora, A Yaba, Jin, Jin Li, G Zheng, J, Y Wang, L Pan, Y Liu, Y Ding, Y Nie, M Yang, M Song, B Zhou, B Li, L Tian, Q Jiang, C Xiong, Y Lv, X Zhang, G Qi, X Zhang, L Wang, F Li, J Guo, T Tang, J Li, Y Yang, L Zhang, Y Quan
{"title":"S100A7 promotes endometrial carcinoma progression by activating the MAPK signaling pathway","authors":"Xiaojing Sun, Xinyue Zhang, Lanhui Yuan, Yu-Qin Fu, N Concin, X Matias-Guiu, I Vergote, D Cibula, M Mirza, S Marnitz, V Makker, M Taylor, C Aghajanian, A Oaknin, J Mier, A Cohn, J Perera, P Hoskin, X Liang, H Zeng, S Chen, M Jiang, S Liu, Fan, Y Zhang, W Zhao, Z Chen, X Zhao, P Ren, M Zhu, J Guo, X Cui, X Zhang, H Qian, H Duan, Y Zhang, F D'amico, E Skarmoutsou, M Libra, G Luo, M Tang, Q Zhao, L Lu, Y Xie, Y Li, Z Lu, S Zheng, C Liu, X Wang, G Zhang, F Wang, K Dey, R Bharti, G Dey, I Pal, Y Rajesh, S Chavan, E Asl, M Amini, S Najafi, B Mansoori, A Mokhtarzadeh, A Mohammadi, H Park, K Baek, J Wang, P Xu, X Yang, Q Yu, X Xu, G Zou, L Gonzalez, K Garrie, M Turner, P Singh, S Ali, S Doi, N Fujioka, S Ohtsuka, R Kondo, M Yamamoto, M Denda, C Allgwer, A Kretz, Von Karstedt, S Wittau, M Henne-Bruns, D Lemke, J, D Dowarha, R Chou, C Yu, D Meng, R Sun, G Liu, L Peng, L Zheng, P Xie, G Huang, J Zhang, G Qing, D Liu, X Wang, Y Chen, H Xu, H Song, Q Zhou, P Huang, J Xue, Y Cong, Y Cui, S Wang, L Jiang, J Cao, S Zhu, Q Sun, Y Cao, Y Lan, L Lei, B Zhang, S Wang, G Peng, S Tsukamoto, K Okumura, H Ogawa, S Ikeda, F Niyonsaba, M Muoio, M Talia, R Lappano, A Sims, V Vella, F Cirillo, S Mishra, M Charan, R Shukla, P Agarwal, S Misri, A Verma, J Anjum, S Mitra, R Das, R Alam, A Mojumder, T Emran, G Bora, A Yaba, Jin, Jin Li, G Zheng, J, Y Wang, L Pan, Y Liu, Y Ding, Y Nie, M Yang, M Song, B Zhou, B Li, L Tian, Q Jiang, C Xiong, Y Lv, X Zhang, G Qi, X Zhang, L Wang, F Li, J Guo, T Tang, J Li, Y Yang, L Zhang, Y Quan","doi":"10.22514/10.22514/ejgo.2023.028","DOIUrl":"https://doi.org/10.22514/10.22514/ejgo.2023.028","url":null,"abstract":"S100 calcium binding protein A7 (S100A7) has been proofed to play a carcinogenic role in several cancers. However, its role and the regulatory mechanism in Endometrial carcinoma (EC) was unknown. Western blot was applied to determine the expression of S100A7 and Mitogen-activated protein kinase (MAPK) pathway-related protein in EC cells. Functional in vitro experiments were conducted to explore the effects of S100A7 on cell proliferation, apoptosis, migration, invasion and angiogenesis in EC. As a result, S100A7 expression was dramatically up-regulated in EC cells. Overexpression of S100A7 enhanced EC cells proliferation, migration, invasion and angiogenesis, and suppressed cell apoptosis, as well as activated MAPK signaling pathway. Whereas, knockdown of S100A7 exerted the opposite effects. Our finding suggested that S100A7 may promote the malignant progression of EC by activating MAPK pathway, implying S100A7 has significant potential to be used as an emerging therapeutic target for EC treatment.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://oss.ejgo.net/files/article/20230417-13/pdf/EJGO2023020204.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147889316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yuanyuan Zuo, Yuejun Sun, Guihong Dai, L Van Wagensveld, G Sonke, K Van De Vijver, H Horlings, Rfpm Kruitwagen, M Van Der Aa, Chunju Xu, X, J Taylor, J Miller, E Ballard, C Byrd, A Holloway, A Smith, C Stewart, C Ralyea, S Lockwood, L Hao, J Wang, B Liu, J Yan, C Li, J Jiang, M Roett, P Evans, S Morand, M Devanaboyina, H Staats, L Stanbery, J Nemunaitis, C Gao, J Shi, J Zhang, Y Li, Y Zhang, Erin Kaser, Marco Lequio, Ziwen Zhu, Zachary Hunzeker, Aidan Heslin, Kyle, H Gao, J Zhang, X Ren, Y Yang, L Xia, Y Wu, H Zhou, X Chen, H Li, L Li, J Wang, Z Zhang, Q Yang, Z Deng, W Zou, H Wang, Z Zhang, Z Yan, S Ma, T Deng, Y Liu, Y Yang, L Yuan, F Liu, X Wang, N Li, P Lin, Z Zuo, M You, W Shuai, R Orlowski, X Liu, D Zhao, K Wang, M Zhang, J Wang, P Sun, J Luo, H Jin, J Zhu, L Yan, Q Wang, C Wan, M Keany, H Dong, L Al-Alem, U Pandya, S Lazo, Y Fujita, S Yagishita, K Hagiwara, Y Yoshioka, N Kosaka, F Takeshita
{"title":"CKS1B promotes the growth of ovarian cancer cells by regulating the expression of PD-L1","authors":"Yuanyuan Zuo, Yuejun Sun, Guihong Dai, L Van Wagensveld, G Sonke, K Van De Vijver, H Horlings, Rfpm Kruitwagen, M Van Der Aa, Chunju Xu, X, J Taylor, J Miller, E Ballard, C Byrd, A Holloway, A Smith, C Stewart, C Ralyea, S Lockwood, L Hao, J Wang, B Liu, J Yan, C Li, J Jiang, M Roett, P Evans, S Morand, M Devanaboyina, H Staats, L Stanbery, J Nemunaitis, C Gao, J Shi, J Zhang, Y Li, Y Zhang, Erin Kaser, Marco Lequio, Ziwen Zhu, Zachary Hunzeker, Aidan Heslin, Kyle, H Gao, J Zhang, X Ren, Y Yang, L Xia, Y Wu, H Zhou, X Chen, H Li, L Li, J Wang, Z Zhang, Q Yang, Z Deng, W Zou, H Wang, Z Zhang, Z Yan, S Ma, T Deng, Y Liu, Y Yang, L Yuan, F Liu, X Wang, N Li, P Lin, Z Zuo, M You, W Shuai, R Orlowski, X Liu, D Zhao, K Wang, M Zhang, J Wang, P Sun, J Luo, H Jin, J Zhu, L Yan, Q Wang, C Wan, M Keany, H Dong, L Al-Alem, U Pandya, S Lazo, Y Fujita, S Yagishita, K Hagiwara, Y Yoshioka, N Kosaka, F Takeshita","doi":"10.22514/ejgo.2023.110","DOIUrl":"https://doi.org/10.22514/ejgo.2023.110","url":null,"abstract":"Ovarian cancer has high rates of morbidity and mortality and a poor prognosis. A growing body of research suggests that CDC28 protein kinase regulatory subunit 1B (CKS1B) influences the progression of numerous carcinomas. However, the specific mechanism of CKS1B in ovarian cancer has yet to be elucidated. Here, this study aimed to investigate the involvement of CKS1B in the progression of ovarian cancer. Initially, we collected data from the Cancer Genome Atlas (TCGA) website and ovarian cancer tissues showed elevated CKS1B expression compared to healthy tissues, indicating a poorer prognosis. Immunohistochemistry (IHC) was used to detect CKS1B and programmed cell death 1-ligand 1 (PD-L1) levels and demonstrated that CKS1B is positively related to PD-L1 expression. Then, short-interfering (si)-CKS1B or si-negative control (si-NC) constructs were transfected into SKOV3 and OVCAR3 cells. Subsequently, cell viability was measured by cell counting kit-8 (CCK8) and colony formation assays, and the extent of apoptosis was assessed using flow cytometry. We found that CKS1B silencing inhibited cell growth and promoted cell apoptosis in ovarian cancer. In addition, the expression levels of CKS1B, B-cell lymphoma-2 (BCL2)-associated X (Bax), cleaved-caspase3 and PD-L1 were determined by western blotting. Furthermore, to investigate whether the inhibitory effects of si-CKS1B on ovarian cancer is related to the levels of PD-L1, we added PD-L1 to si-CKS1B transfected cells and found that cells that had been supplemented with PD-L1 exhibited an increased cell growth rate and a reduced apoptosis rate than si-CKS1B cells. Collectively, our data we demonstrated high levels of CKS1B in ovarian cancer cells, and found that the knockdown of CKS1B could alleviate the development of ovarian tumors by dysregulating the level of PD-L1 expression.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"44 6","pages":"150-150"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://oss.ejgo.net/files/article/20231215-129/pdf/EJGO2023080801.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147905139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Bioinformatics analysis of the diagnostic significance and functions of RDH5 in breast cancer","authors":"","doi":"10.22514/ejgo.2023.054","DOIUrl":"https://doi.org/10.22514/ejgo.2023.054","url":null,"abstract":"Objective: RDH5 (Retinol dehydrogenase 5) is one of the member of the short-chain dehydrogenase/reductase (SDR) family and plays a critical role in a variety of tumor processes. In this study, we analyzed the expression, diagnostic significance and gene function of RDH5 in breast cancer. Methods: The Gene Expression Profiling Interactive Analysis (GEPIA) database was used to determine the diagnostic and prognostic value of RDH5 and the University of Alabama at Birmingham (UALCAN) database analyzed its expression in different subtypes, clinical stages and altered signal pathways in breast cancer. Then we explored the co-expression gene of RDH5 in breast cancer and constructed its corresponding network through the cBioPortal database. The String database was used to determine its interactions with other proteins. Results: RDH5 expression was differentiated in various tumours compared to normal tissue, and was down-regulated in breast cancer tissue and different subtypes of breast cancer. There was no correlation between RDH5 and the survival of breast cancer. RDH5 expression was significantly associated with different clinical parameters. Additionally, the protein expression of RDH5 in breast cancer with altered pathways indicated it was closely associated with the SWI-SNF (switching/sucrose non-fermenting) complex status and the mammalian Target of Rapamycin (mTOR), WNT (Wingless/Integrated), MYC/MYCN (Myelocytomatosis oncogene/euroblastoma derived MYC), RTK (receptor Tyrosine kinases), and p53/Rb (tumor protein p53/Retinoblastoma) pathways. Interaction analysis with RDH5 and its co-expression genes showed that its main related functions were ethanol oxidation, regulation of heart contraction and negative regulation of tumor necrosis factor. Lastly, the Protein-protein interaction (PPI) of RDH5 showed that the most relevant Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were retinol metabolism, vitamin digestion and absorption and metabolic pathways. Conclusion: These results implied that RDH5 might be a larvaceous diagnostic biomarker for breast cancer and was closely associated with its metabolism. However, more studies are needed to confirm our findings and support the clinical importance of RDH5 in breast cancer.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"44 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Overexpression of LINC01234 in uterus corpus endometrial cancer correlated with poor clinicopathological characteristics: a study based on TCGA data","authors":"","doi":"10.22514/ejgo.2023.057","DOIUrl":"https://doi.org/10.22514/ejgo.2023.057","url":null,"abstract":"Uterus corpus endometrial cancer (UCEC) is associated with a high mortality rate. In this study, we examined the impact of long intergenic non-protein coding RNA 01234 (LINC01234) in the diagnosis and survival of UCEC using an open high-throughput sequencing database. The association between LINC01234 expression and UCEC clinical features was determined using the Wilcoxon rank sum test, logistic regression and Cox regression. To assess the classification effectiveness of LINC01234 in UCEC, the area under the receiver operating characteristic (ROC) curve (AUC) was performed. Then, Kaplan-Meier analysis was performed to determine the prognostic significance of LINC01234 in UCEC. The underlying regulatory mechanisms of LIN01234 were assessed using the Gene set enrichment analysis (GSEA), and the influence on immune infiltration cells was tested by the Spearman correlation method. Datebases showed LINC01234 was up-regulated in UCEC and associated with poor clinicopathologic characteristics. What’s more quantitative real time polymerase chain reaction (qRT-PCR) analyse of clinical tissue specimens, LINC01234 was actually high expression in UCEC. The results showed an AUC of 0.726, indicating that LINC01234 had a significant diagnostic value. Further, Kaplan-Meier analysis showed that high LINC01234 expression was associated with poorer progress free interval (PFI) (hazard ratio (HR): 1.68, 95% confidence interval (CI): 1.18–2.39, p = 0.004), disease-specific survival (DSS) (HR: 2.17, 95% CI: 1.29–3.67, p = 0.004), overall survival (OS) (HR: 1.81, 95% CI: 1.19–2.75, p = 0.005). Cox regression analysis showed LINC01234 expression was an independent factor for DSS. Pathway enrichment and immune infiltration analysis showed the most likely mechanisms that LINC01234 promoted tumor progression. LINC01234 demonstrated diagnostic and prognostic potential in UCEC and was shown to exert its effects via various mechanisms, including cell proliferation, spermatogenesis, angiogenesis and immune response in the tumor microenvironment, to promote tumor progression; thus, indicating that it could be a target for treating UCEC.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"184 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Transcriptome analysis constructed the necroptosis associated prognostic signature in endometrial cancer and identified EZH2 as a potential biomarker","authors":"","doi":"10.22514/ejgo.2023.060","DOIUrl":"https://doi.org/10.22514/ejgo.2023.060","url":null,"abstract":"Endometrial cancer (EC) is one of the most common malignancies of the female reproductive system, but our understanding of the tumor microenvironment of EC remains unclear. Programmed cell death (PCD) plays an important role in the genesis and progression of tumors. Necroptosis is a novel form of PCD that does not rely on the caspase system. However, the role of necroptosis in EC is unclear. Transcriptome data of endometrial cancer were downloaded from The Cancer Genome Atlas (TCGA) database and log2 conversion was performed. Expression analysis and correlation analysis were performed to explore necroptosis gene expression and interaction in EC. Lasso regression was used to construct necroptosis-related prognostic signature. Finally, immunocorrelation analysis and single cell sequencing analysis were used to explore the significance of this signature in EC tumor microenvironment. A total of 15 of the 17 necroptosis genes were differentially expressed in EC. Subsequently, necroptosis related prognostic signature was constructed through Lasso regression. Riskscore = (−0.0999) × Toll-likereceptor4 (TLR4) + (−0.0528) × tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) + (0.1208) × Enhancer of Zeste Homolog 2 (EZH2) + (−0.004) × N-myc Down-stream Regulated Gene 2 (NDRG2). EC patients can be divided into high-risk group and low-risk group based on the median riskscore and the high-risk group has a worse prognosis. Survival analysis showed a worse prognosis for patients in the high-risk group (p < 0.05). Immunomicroenvironment analysis showed a significant negative correlation between risk score and infiltration levels of B cells, CD4+ T cells, CD8+ T cells, Endothelial cells, macrophages, and NK cells. Subsequent cell experiments showed that knockdown of the key gene EZH2 in signature significantly reduced the invasion, migration and healing abilities of EC cell lines, proving that EZH2 is a promising marker of EC.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136115276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Human papilloma virus associated primary vaginal adenocarcinoma","authors":"","doi":"10.22514/ejgo.2023.091","DOIUrl":"https://doi.org/10.22514/ejgo.2023.091","url":null,"abstract":"Primary vaginal adenocarcinoma associated with human papillomavirus (HPV) infection is extremely rare. We report a case of primary adenocarcinoma of the vagina associated with human papilloma virus successfully treated with anterior pelvic exenteration and adjuvant concurrent chemoradiation therapy. A 51-year-old postmenopausal woman (gravida 1, para 1) presented with intermittent vaginal bleeding and pelvic pain. She was found to have a 5 × 5 cm necrotic tumor took up the vaginal. She had no previous history of antenatal exposure to diethylstilbestrol (DES). Pelvic magnetic resonance imaging (MRI) demonstrated a 4.8 × 6.0 cm mass in the vaginal canal, an 1.1 × 2.6 cm mass at the urinary bladder dome and a 1.1 cm irregular lymph node at the right external iliac chain with increased fluorodeoxyglucose (FDG) uptake from Fused whole-body positron emission tomography-computed tomography (PET-CT). Based on clinical investigations, the patient was diagnosed with a primary adenocarcinoma of vagina, staged International Fedestration of Gynecology and Obstetrics (FIGO) IVa. Anterior pelvic exenteration, simple vulvectomy, total vaginectomy, both pelvic lymph node dissection, and para-aortic lymph node dissection with ileal conduit urinary diversion (Bricker’s operation) was done. Histologically primary vaginal HPV type 16-associated adenocarcinoma was confirmed. Both obturator lymph node was positive for metastasis. Postoperatively, the patient received weekly cisplatin regimen administered with a dose of 40 mg/m2 on day 1 of external radiation therapy (RT), 1 to 4 hours before RT initiation. External beam pelvic RT dose prescription to the whole pelvis was 59.4 Gy in 33 fractions at the isocenter. But, after total dose of 43.2 Gy, patient complained severe bowel habit change and discontinued further treatment. The patient remains free from recurrence 8 months after initial surgery. In the lack of information and comparative analysis of management options for the more unusual and rare varieties of primary vaginal neoplasms in the literature, this suggests the possibility that surgical treatment may be preferentially selected on a case-by-case basis.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"21 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136366312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Inhibition of MARK2 inhibits ovarian cancer cell proliferation by regulating PI3K/AKT/p53 axis","authors":"","doi":"10.22514/ejgo.2023.088","DOIUrl":"https://doi.org/10.22514/ejgo.2023.088","url":null,"abstract":"Ovarian cancer (OC) is the 3rd most common type of the gynecological malignancy. Although current treatment strategies have greatly improved, there is still a need to develop new biomarkers for OC diagnosis and treatment. Microtubule affinity regulated kinase 2 (MARK2) is a kinase involved in the progression of multiple tumors. However, whether abnormal expression of MARK2 is associated with OC progression needs further analysis. We here revealed its role in OC. We found high expression of MARK2 in OC. Knockdown of MARK2 inhibited proliferation of OC cells, stimulated apoptosis of OC cells, and restrained glucose metabolism of OC cells. Furthermore, MARK2 regulated phosphatidylinositol 3-kinase/PKB (protein kinase B)/tumor suppressor protein 53 (PI3K/AKT/p53) axis in OC, therefore affecting the progression of OC. In summary, MARK2 knockdown suppressed cell proliferation by regulating PI3K/AKT/p53 axis.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136368243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The infrequent large pelvi-perineal tumors as a surgical dilemma: en bloc resection and long-term results","authors":"","doi":"10.22514/ejgo.2023.052","DOIUrl":"https://doi.org/10.22514/ejgo.2023.052","url":null,"abstract":"To assess long-term results of surgical resections of the sporadic extra-large pelvi-perineal soft tissue tumors, a retrospective series of patients referred to the National Cancer Institute 2001–2022 (tertiary care cancer university hospital in Egypt) was designed. Thirteen patients (3 males) averaged age 57 years had large 29 cm (18–38) pelvi-perineal tumors (10 to the paraanal ischiorectal spaces and 3 to the vulva) plus upper intra-abdominal extensions in 9 patients (69%). Symptoms were nonspecific with delayed presentation that averaged 22-month. The entire underwent combined open abdomino-perineal approach to widely en masse resect tumors plus infiltrated organs. No downsizing hormonal treatment was offered preoperative. Main outcome measures were disease free survival, recurrence pattern and salvage. Extensive pelvic and perineal tumor resection is tough and meticulous but straightforward with minor (Clavien-Dindo Classification (CDC) grade I & II) early and delayed morbidity. Resection extends to hysterectomy, vaginectomy and vascular resection. Histopathology plus immunohistochemistry showed 9-aggressive angiomyxoid tumors (AA), 2-fibromatosis and 2-neurofibromas (NF). Margins of resection are all adequate (R0) except for 2 (Resection margin 1 (R1)). After 50-month median follow up, 8/13 total series (61.5%) were surviving free of disease. 4/9 of AA (44%) had local perineal and/or pelvic recurrences (13–37 months) and all were amenable to curative salvage resections; while, 1/2 patients with fibromatosis died of disseminated peritoneal relapses. No systemic metastases are noticed. Extensive tumors meticulous surgery with experienced pelvic dissection and resection could offer alone long term cure even after recurrences with minor morbidity in a good percent. Fertility sparing resection is not oncologically safe because of the frequent uterine and ovarian invasions.","PeriodicalId":11903,"journal":{"name":"European journal of gynaecological oncology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135828090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}